Botox (onabotulinumtoxinA) for Muscle Spasms in Multiple Sclerosis

The botulinum toxin, also known as Botox (onabotulinumtoxinA), is approved by the FDA to treat muscle spasms, spasticity, and bladder symptoms in patients with a wide range of diseases including multiple sclerosis (MS). The therapy is based on the bacteria Clostridium botulinum — a toxin that blocks neuromuscular conduction between the nerves and the muscles. The therapeutic result is a short-term localized relaxation of the targeted muscle.

Botox is manufactured by Allergan. The prescription medicine is injected into the muscles to treat increased muscle stiffness in ankle and toe muscles in adults with lower limb spasticity, and in elbow, wrist, finger, and thumb muscles in adults with upper limb spasticity.

There are no studies yet that confirm Botox’s safety and effectiveness for treating upper limb muscles other than those in the elbow, wrist, and thumb, or to treat increased stiffness in lower limb muscles other than ankle and toes.

Botox is injected approximately once every three months directly into the affected muscles by a healthcare specialist. The treatment can be repeated once the effect has worn off, but no sooner than three months in between injections.

Botox for muscle spasms in MS: What to know

The effects of the botulinum toxin may spread from the area of injection and produce symptoms that may last weeks after injection. Swallowing and breathing difficulties can be life threatening. Children treated for spasticity may have a greater risk, but risk can also occur in adults.

The most common adverse reactions reported by patients with spasticity are nausea, fatigue, bronchitis, muscle weakness, and pain in the arms.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

Third Phase 3 Trial of Sativex, Cannabis Extract for MS Spasticity, Planned

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5 trial (NCT04984278) is expected to enroll about 190 adults with any […]

Sativex Eased MS Spasticity as an Add-on Therapy

Sativex (nabiximols), an oral spray that contains cannabis extracts, was found effective as an add-on therapy for easing spasticity in adult multiple sclerosis (MS) patients who failed to respond to other anti-spastic treatments, a real-world study from Belgium reports. Overall, about 74% patients reported easing of spasticity — muscle stiffness or spasms —after 12 weeks of treatment, defined as […]

Medical Cannabis in Greece Will Be Sold Under Brand Name Panaxir

Medical cannabis made by Panaxia Labs Israel will be marketed and distributed in Greece by Leriva Group, under a recent agreement between the two companies and pending a marketing authorization in the country. The product will be sold under the brand name Panaxir. The companies expect to start selling the first Panaxir products in 2022 […]

More Trials Needed to Clarify Benefits of Alzheimer’s Therapy Memantine in MS

Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline and disability, and to significantly reduce fatigue and spasticity in adults with multiple sclerosis (MS), a review of published studies shows. The therapy, sold under the brand name Namenda, works by preventing glutamate — a nerve-signaling molecule previously […]

GW Pharma Plans More Clinical Trials for Sativex

GW Pharmaceuticals is planning to continue recruiting patients into two pivotal Phase 3 clinical trials of Sativex (nabiximols), an oral spray that contains cannabis extracts and is being investigated as a potential add-on therapy for people with multiple sclerosis (MS) and spasticity. The company also is planning to launch three additional clinical trials in the U.S. […]

Phase 3 Trial of Sativex, Cannabis Extract Treatment for MS Spasticity, Opens in US

A Phase 3 trial is underway in the U.S. to assess the safety and efficacy of Sativex (nabiximols), an oral spray that contains cannabis extracts, in treating spasticity — muscle stiffness or spasms — associated with multiple sclerosis (MS). Sativex, by GW Pharmaceuticals, is available in 25 countries — including most of Europe and Canada — as […]

FDA Will Review Arbaclofen ER, Potential Oral Therapy for MS Spasticity

The U.S. Food and Drug Administration (FDA) has agreed to review  Osmotica Pharmaceuticals‘ amended request for the approval of arbaclofen extended release (ER) tablets to treat spasticity in people with multiple sclerosis (MS), the company announced. The regulatory agency found that the new drug application addressed all issues raised in a July 2016 action letter response to the […]

Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS). The money, worth about […]

Osmotica Amends NDA for Arbaclofen ER to Treat MS Spasticity

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name Ontinua), is an extended release formulation of arbaclofen, a compound similar to the muscle […]

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These flash briefings give our readers an alternative option for accessing information important for them.

Listen Here

Survey Icon

Video